Letrozole and Anastrozole in Early Breast Cancer Post-menopausal Patients in Oncology Department at Suez Canal University Hospital

Montasser, Manar; Hassanin, Ehab M; Abdelmohsen, Soheir E; Zamzam, Maha L

doi:10.21608/scumj.2018.43356

Letrozole and Anastrozole in Early Breast Cancer Post-menopausal Patients in Oncology Department at Suez Canal University Hospital

Document Type : Original Article

Authors

Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Suez Canal University, Egypt

10.21608/scumj.2018.43356

Abstract

Background:There are limited data in the literature comparing the efficacy of aromatase inhibitors in postmenopausal hormonal receptor positive early breast cancer patients. Aim: To compare the efficacy of letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients. Patients and Methods: A retrospective study with a mean follow-up period of 64 months (about 5 years) for 74 files of early invasive postmenopausal breast cancer hormonal receptor positive patients; 39 received letrozole and 35 received anastrozole, considering TTP as primary end point, and OS as second end points. Results: Letrozole is not superior to anastrozole during the first 55 months of treatment (80% PFS at 5^th year), and 80% OS benefit at 6^th year.. Overweight patients had better (90% PFS at 5^th year) than obese patients (60% PFS at 5^th year). Conclusion: Letrozole is not superior to anastrozole in efficacy in early invasive hormonal receptor positive breast cancer postmenopausal patients during the first 5 years of treatment; however, Letrozole 2^nd line after tamoxifen is superior to anastrozole 2^nd line after tamoxifen in treating obese patients with early invasive hormone receptor positive breast cancer.

Keywords